Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia Single Center, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Doses of HC022 in Healthy Subjects

NCT06657703 is registered in ClinicalTrials.gov with HC Biopharma Inc. as lead sponsor.

NCT NCT06657703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06657703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia Single Center, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Doses of HC022 in Healthy Subjects
Lead sponsor
HC Biopharma Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 25, 2024
Completion date
January 8, 2026
Enrollment
38 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus